Neumora Therapeutics (NMRA) EBT (2022 - 2026)
Neumora Therapeutics' quarterly EBT came in at -$53.4 million in Q1 2026, up 21.3% year-on-year from -$44.0 million in Q1 2025, and up 10.13% quarter-over-quarter from -$59.4 million in Q4 2025.
Neumora Therapeutics has reported EBT for 5 years, with the latest figure at -$53.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 21.3% year-over-year to -$53.4 million; the trailing twelve-month figure through Mar 2026 stood at -$222.3 million (up 13.75% YoY), and the FY2025 full-year result was -$236.8 million, up 2.8% from the prior year.
- EBT for Q1 2026 stood at -$53.4 million, up from -$59.4 million in the prior quarter.
- The five-year high for EBT was -$28.4 million in Q4 2022, with the low at -$108.5 million in Q4 2023.
- Average EBT over 5 years is -$55.1 million, with a median of -$53.7 million recorded in 2024.
- Year-over-year, EBT plunged 281.47% in 2023 and soared 45.77% in 2024.
- Tracing NMRA's EBT over 5 years: stood at -$28.4 million in 2022, then sank by 281.47% to -$108.5 million in 2023, then soared by 45.77% to -$58.8 million in 2024, then fell by 1.07% to -$59.4 million in 2025, then climbed by 10.13% to -$53.4 million in 2026.
- The last three EBT figures came in at -$53.4 million (Q1 2026), -$59.4 million (Q4 2025), and -$56.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -53.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.43 Mn |
| Dec 31, 2025 | -59.45 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.71 Mn |
| Mar 31, 2025 | -67.89 Mn |
| Dec 31, 2024 | -58.82 Mn |
| Sep 30, 2024 | -72.49 Mn |
| Jun 30, 2024 | -58.58 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -35.60 Mn |
| Dec 31, 2022 | -28.43 Mn |
| Sep 30, 2022 | -29.20 Mn |